In vivo neuropharmacology of schizophrenia
Bigliani, V.; Pilowsky, L.S.
British Journal of Psychiatry. Suppl 38: 23-33
1999
ISSN/ISBN: 0960-5371 PMID: 10884897 Document Number: 505663
Document emailed within 1 workday
Related Documents
Benabid, A.L.; Rémy, C.; Decorps, M.; Lotito, S.; Blondet, P.; von Kienlin, M.; Francois, A.; Albrand, J.P.; Le Bas, J.F. 1987: Application of in vivo NMR spectroscopy to neuropharmacology in rats Therapie 42(5): 471-476Sedvall, G. 1986: Neuropharmacology and the human brain Acta Psychiatrica Scandinavica. Supplementum 327: 11-18
Lucignani, G.; Moresco, R.M.; Fazio, F. 1989: PET-based neuropharmacology: state of the art Cerebrovascular and Brain Metabolism Reviews 1(4): 271-287
Slikker, W.; Paule, M.G. 1985: Developmental neuropharmacology/neurotoxicology Proceedings of the Western Pharmacology Society 28: 309-310
Habibuddin, M.; Pal, M.; Pal, S.P. 1992: Neuropharmacology of amide derivatives of P-GABA Indian Journal of Experimental Biology 30(7): 578-582
Mashkovskiĭ, M.D. 1988: Stages in the development of Soviet neuropharmacology Farmakologiia i Toksikologiia 51(2): 5-15
Zirvi, K.A.; Jarboe, C.H. 1976: Synthesis and neuropharmacology of cyclobutanecarboxylic acid derivatives Il Farmaco; Edizione Scientifica 31(2): 152-158
Poewe, W.; Lees, A.J.; Steiger, D.; Stern, G.M. 1987: Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology Advances in Neurology 45: 357-360
Mandell, A.J.; Knapp, S. 1982: Regulation of tryptophan hydroxylase: variational kinetics suggest a neuropharmacology of phase Advances in Biochemical Psychopharmacology 34: 1-15
Delorenzo, R.J. 1975: Possible correlation between protein D phosphorylation and membrane permeability changes to sodium ions in the toad bladder and its relationship to neuropharmacology Bulletin of the Parenteral Drug Association 29(5): 250-260
Schooler, N.R.; Keith, S.J.; Severe, J.B.; Matthews, S. 1989: Acute treatment response and short term outcome in schizophrenia: first results of the NIMH treatment strategies in schizophrenia study. Treatment Strategies in Schizophrenia Collaborative Study Group Psychopharmacology Bulletin 25(3): 331-335
Zaytseva, Y.; Burova, V.; Garakh, Z.; Gurovich, I.Y. 2013: Attributional style in fist episode of schizophrenia and schizophrenia spectrum disorders with and without paranoid ideation Psychiatria Danubina 25(Suppl 2): S329-S331
Roxo, H. 1952: Pseudoneurotics; patients at the onset of schizophrenia; differential diagnosis of neurasthenia and schizophrenia; modern therapy Imprensa Medica 28(463): 25-30
Tsirkin, S.Iu. 1987: International study of schizophrenia based on a WHO program. Incidence of schizophrenia Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 87(8): 1203-1207
Kotlicka-Antczak, M.; Rabe-Jabłońska, J. 1997: Neurodevelopmental schizophrenia: the concept of developmental origins of certain forms of schizophrenia Psychiatria Polska 31(5): 527-538
Steinborn, B.; Galas-Zgorzalewicz, B. 2000: Therapeutic antiepileptic drug monitoring: thirteen years of experience in the Laboratory of Clinical Neuropharmacology in the Chair and Department of Developmental neurology Neurologia i Neurochirurgia Polska 34 Suppl. 1: 49-59
Arraras, J.I.; Basterra, I.; Pereda, N.; Ibañez, B.; Iribarren, S.; Cabases, J.M. 2019: The Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4) questionnaire. A validation study with Spanish schizophrenia spectrum outpatients Actas Espanolas de Psiquiatria 47(3): 97-109
Suzuki, S. 1982: The mental maturation and verbal alteration in a mild case of chronic non-paranoiac schizophrenia. a linguistic-phenomenological approach to the concept of schizophrenia simplex Seishin Shinkeigaku Zasshi 84(1): 1-19
Hargreaves, W.A.; Kane, J.M.; Ninan, P.T.; Severe, J.B.; Woerner, M. 1989: Demographic characteristics, treatment history, presenting psychopathology and early course in schizophrenia. Treatment Strategies in Schizophrenia Collaborative Study Group Psychopharmacology Bulletin 25(3): 340-343
Williams, J.; Spurlock, G.; McGuffin, P.; Mallet, J.; Nöthen, M.M.; Gill, M.; Aschauer, H.; Nylander, P.O.; Macciardi, F.; Owen, M.J. 1996: Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group Lancet 347(9011): 1294-1296